Quick answer: Dose-Response Curves for Grayanotoxin: What the Research Actually Shows
Grayanotoxin dose-response is non-linear because the target (voltage-gated sodium channels) saturates. The curve is shallow in the low-dose range (mild symptoms across a wide dose window) and steep once saturation threshold is reached (rapid escalation of severity). Individual variability is substantial — a threefold difference in threshold between individuals is plausible — driven by genetic polymorphisms in CYP3A4, channel subtype expression, and autonomic tone. "A little more" at the wrong point on the curve can mean "a lot more effect."
Why dose-response matters for a food product
Most foods are at doses where pharmacological effects are negligible. Mad honey is different — a typical serving produces a measurable pharmacologic effect, and the relationship between "how much you took" and "how much effect you got" is not a straight line.
I want to walk through what the literature actually suggests the curve looks like and why understanding it matters for safety.
The shape of the curve
For most drugs with a receptor target, the dose-response curve is sigmoidal on a log scale. Below the threshold of receptor occupancy, effect is minimal; as occupancy increases, effect rises rapidly; past saturation, additional drug produces no additional effect but may produce toxicity.
Grayanotoxin follows this general pattern, but with three complications:
- Multiple grayanotoxin isoforms (I, II, III) have different potencies. Different honeys have different ratios.
- Multiple target channel subtypes (Nav1.5 in cardiac tissue, Nav1.7 and others in neuronal) have different binding affinities.
- Pharmacokinetic variability (CYP3A4 activity) shifts the curve horizontally between individuals.
The net result: the "typical" curve is an averaged artifact. Your actual curve may be shifted left or right by a factor of 2–3 from the typical.
What the threshold looks like in practice
Case-series data cluster symptom thresholds roughly as follows for high-potency Nepalese honey:
- Below 5 g: most users report minimal or no effects.
- 5–15 g: mild to moderate effects in most users; sensitive users may experience significant effects.
- 15–30 g: moderate effects in most users; symptomatic bradycardia in sensitive users.
- 30–60 g: significant effects in most users; ED presentations become likely.
- Above 60 g: high rate of significant adverse events in published case series.
Turkish deli-bal is roughly 2–4x less potent per gram. Bhutanese honey is believed to be comparable to Nepalese. Individual batches vary within each origin.
Why the curve is steep past threshold
Voltage-gated sodium channels are an all-or-nothing target at the individual channel level. Once grayanotoxin binds, the channel stays open. As dose increases, the fraction of channels "stuck open" increases non-linearly because of cooperativity and tissue-specific distribution. The transition from "a little sleepy" to "bradycardic" is often a narrow dose range.
Practically, this means the margin between a mild dose and an uncomfortable dose can be surprisingly small if you're operating near your individual threshold.
Individual variability — the factor that matters most
Three sources of variability I see in the clinical literature:
- CYP3A4 polymorphisms. Roughly 10–15% of Caucasians and higher fractions of other ancestries carry variants that significantly alter CYP3A4 activity. Slow metabolizers get higher plasma levels per unit dose.
- Autonomic tone. Athletes with high resting vagal tone start closer to the bradycardia threshold. They experience more pronounced heart-rate effects.
- Age. Elderly patients have reduced hepatic metabolism and often pre-existing conduction disease. Both shift the threshold left.
The "minimum effective dose" question
Users often ask for the minimum dose that produces noticeable effects. For high-potency Nepalese honey, the typical answer is 2–3 g. Below that most people report nothing. For deli-bal, the typical answer is 5–8 g.
But "typical" conceals variability. Some people report distinct effects from a single gram. A few don't respond until 10 g. This is the main reason a first-time user should start at 1 g: you genuinely don't know where you sit on the distribution until you measure.
Why re-dosing in a session is risky
If your first dose produced no effect, the instinct is to take more. The problem is that you may be on the shallow part of the curve — the part where small additional doses produce small additional effects — right up until you hit threshold, at which point a small additional dose produces a disproportionately larger effect.
The 2-hour re-dose rule I discuss in the pharmacokinetics post is partly about avoiding this transition.
Bottom line
Grayanotoxin dose-response is non-linear, tissue-dependent, and individually variable. Treat any new batch as a fresh titration. Assume your threshold might be lower than average. Don't chase effect by re-dosing within a session. The curve rewards patience.
